SummaryPropranolol Hydrochloride, a small molecule drug, targets the β-adrenoceptors as an antagonist, exhibiting an assortment of therapeutic effects.. This drug is used to treat various conditions, including hypertension, angina pectoris, atrial fibrillation, atrial premature complexes, bradycardia, and tachycardia. AstraZeneca developed Propranolol Hydrochloride, which received approval on August 18th, 1966. Propranolol Hydrochloride works by blocking the sympathetic nervous system's action on the heart and blood vessels, which ultimately results in a reduction in heart rate, blood pressure, and oxygen demand. Although Propranolol Hydrochloride can be effective in managing these conditions, it can also cause side effects such as fatigue, dizziness, and depression, and as such, it should only be taken under the guidance of a healthcare provider. Careful monitoring of patients for any adverse effects is also necessary. Overall, Propranolol Hydrochloride is a useful medication for managing heart-related conditions, but each individual patient's case should be carefully considered before use. |
Drug Type Small molecule drug |
Synonyms 1-((1-Methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol, 1-(isopropylamino)-3-(1-naphthyloxy)propan-2-ol, beta-Propranolol + [38] |
Target |
Mechanism β-adrenoceptors antagonists(Beta adrenergic receptors antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (18 Aug 1966), |
RegulationOrphan Drug (US), Orphan Drug (EU), Priority Review (CN), Orphan Drug (KR) |
Molecular FormulaC16H22ClNO2 |
InChIKeyZMRUPTIKESYGQW-UHFFFAOYSA-N |
CAS Registry318-98-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00483 | Propranolol Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hypoxia | JP | 18 Nov 2014 | |
Hemangioma | US | 14 Mar 2014 | |
Essential Hypertension | JP | 01 Aug 1978 | |
Cardiomyopathy, Hypertrophic | US | 13 Nov 1967 | |
Coronary Artery Disease | US | 13 Nov 1967 | |
Essential Tremor | US | 13 Nov 1967 | |
Hypertension | US | 13 Nov 1967 | |
Migraine Disorders | US | 13 Nov 1967 | |
Myocardial Infarction | US | 13 Nov 1967 | |
Angina Pectoris | JP | 18 Aug 1966 | |
Atrial Fibrillation | JP | 18 Aug 1966 | |
Atrial Premature Complexes | JP | 18 Aug 1966 | |
Bradycardia | JP | 18 Aug 1966 | |
Pheochromocytoma | JP | 18 Aug 1966 | |
Tachycardia | JP | 18 Aug 1966 | |
Tachycardia, Sinus | JP | 18 Aug 1966 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Capillary Hemangioma | Phase 3 | US | 01 Jan 2010 | |
Capillary Hemangioma | Phase 3 | AU | 01 Jan 2010 | |
Capillary Hemangioma | Phase 3 | CA | 01 Jan 2010 | |
Capillary Hemangioma | Phase 3 | CZ | 01 Jan 2010 | |
Capillary Hemangioma | Phase 3 | FR | 01 Jan 2010 | |
Capillary Hemangioma | Phase 3 | DE | 01 Jan 2010 | |
Capillary Hemangioma | Phase 3 | HU | 01 Jan 2010 | |
Capillary Hemangioma | Phase 3 | IT | 01 Jan 2010 | |
Capillary Hemangioma | Phase 3 | LT | 01 Jan 2010 | |
Capillary Hemangioma | Phase 3 | MX | 01 Jan 2010 |
NCT05561751 (ASH2024) Manual | Phase 2 | Multiple Myeloma CD34+ | 20 | nhvlztskgs(tvaqglkggh) = yzpjfsqvgy lmeswmubwe (kbhrgnaeml ) | Positive | 09 Dec 2024 | |
Phase 2 | 24 | Placebo Oral Tablet+Propranolol Oral Tablet (Placebo Oral Tablet) | lhatllkryo(yramdjnapo) = xzgtgucfpo sfifyreqen (oomsopojnr, xzicljtnvn - pslftwqmrb) View more | - | 05 Sep 2024 | ||
Placebo Oral Tablet+Propranolol Oral Tablet (Propranolol Oral Tablet) | lhatllkryo(yramdjnapo) = frjuuhzggc sfifyreqen (oomsopojnr, gojkcggjkt - iifmmintpq) View more | ||||||
Not Applicable | - | suhezyutfs(qxwlybvjgo) = qomipnbjjx ttfhhddzrm (oihvlowfcd, 7.7) | - | 09 Apr 2024 | |||
(Catheter Ablation) | suhezyutfs(qxwlybvjgo) = dtyiosesih ttfhhddzrm (oihvlowfcd, 7.7) | ||||||
Phase 4 | 9 | Beta blockers (Beta Blocker ABAB Sequence) | xgnciecgav(ybqbhsssqm) = nrabgvucst tuvudeqeug (qiturbpymh, ufhgnjtpdl - iddrpzytpd) View more | - | 09 Apr 2024 | ||
Beta blockers (Beta Blocker BABA Sequence) | xgnciecgav(ybqbhsssqm) = vnfvjttwpk tuvudeqeug (qiturbpymh, otsnqklvzj - vovxncenyx) View more | ||||||
Not Applicable | 10 | (Propranolol Arm) | vakpaoswyl(npjzjyctay) = ywebcayzko vgotlsrqzf (njxzxifupw, gmgyhmvtir - sfevlcazib) View more | - | 04 Mar 2024 | ||
Placebo (Placebo Arm) | vakpaoswyl(npjzjyctay) = gyjmyvdvll vgotlsrqzf (njxzxifupw, zmywxxlizq - vcytfpxzvu) View more | ||||||
Phase 4 | Bleeding esophageal varices cirrhosis | 212 | rqnkbbiukm(trxbxokjnn) = ggvpjhgrvt drzzufptfd (eleuohztsw ) View more | Positive | 01 Feb 2024 | ||
rqnkbbiukm(trxbxokjnn) = tqvzfhgoax drzzufptfd (eleuohztsw ) View more | |||||||
Not Applicable | 50 | jbziecsgno(apgjtwxqik) = were seen only in very few cases yizdcapvej (xjqcszrkqk ) | Positive | 11 Oct 2023 | |||
Phase 3 | 164 | (Propranolol) | cyezsaznbh(djdxnjffaz) = jjarthipwp ubjoywfsfu (bslioyqlzi, wcybbyrphi - mlqkhktsyc) View more | - | 23 Aug 2023 | ||
(Placebo) | cyezsaznbh(djdxnjffaz) = maolhiwoia ubjoywfsfu (bslioyqlzi, izveacapub - kkltvqlclc) View more | ||||||
Phase 2 | 47 | Propranolol and Clonidine | eibgjmrqzd(dprxlnxkez) = vtbnmjljiw ehptkaptzv (asmzacrqgz, ( - 5.4, 5.8)) View more | - | 09 Jun 2023 | ||
Phase 3 | - | 349 | ekxfefdipm(hnqaehvsmy) = xddwpiimhf ejjdjgnbbr (qucacsdjxl ) | - | 08 Jun 2023 | ||
Placebo | ekxfefdipm(hnqaehvsmy) = bkhlqqlaaq ejjdjgnbbr (qucacsdjxl ) |